Pfizer, BioNTech updated COVID vaccine authorized in Canada

Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized the KP.2 variant adapted Comirnaty COVID-19 vaccine for ages six months and older. The updated Comirnaty vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages, the company said in a statement. The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals five years of age and older, regardless of prior COVID-19 vaccination history. For children six months through four years of age, Comirnaty is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.